EP4466255A1 — Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof
Assigned to Innovative Molecules GmbH · Expires 2024-11-27 · 1y expired
What this patent protects
The present invention provides solid crystalline forms of compounds useful as helicase-primase inhibitors, compositions thereof, methods of producing the same, and methods of using the same in the treatment of herpes simplex infection and -mediated diseases.
USPTO Abstract
The present invention provides solid crystalline forms of compounds useful as helicase-primase inhibitors, compositions thereof, methods of producing the same, and methods of using the same in the treatment of herpes simplex infection and -mediated diseases.
Drugs covered by this patent
- Livtencity (MARIBAVIR) · Takeda
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.